TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04061031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Description: A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-Centered Therapy with Parent Education
Description: A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
Study: NCT00788138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 250,000 IU of vitamin D3
Study: NCT00648492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg
Description: 500mg, single dose fed
Study: NCT00788138

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT03534843

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.

Intervention type: OTHER
Intervention: Transcatheter arterial embolization
Description: Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
Study: NCT00462124

Intervention type: DEVICE
Group type: OTHER
Intervention: Absorbable perirectal spacer
Description: biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
Study: NCT03906578

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with similar appearance to probiotic
Study: NCT05937997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high intensity physiotherapy
Description: high intensity exercises for 3 weeks inpatient rehabilitation
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
Study: NCT05937997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity physiotherapy
Description: moderate intensity exercises for 3 weeks inpatient rehabilitation
Study: NCT03742271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: TEST Lens
Study: NCT05937997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low intensity physiotherapy
Description: low intensity exercises for 3 weeks inpatient rehabilitation
Study: NCT02676583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Closure or not closure of tonsil fossa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Closure or not closure of tonsil fossa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Closure or not closure of tonsil fossa
Study: NCT03501992

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined reminder-recall and audit-and-feedback
Description: The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined reminder-recall and audit-and-feedback
Description: The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
Study: NCT04472650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a free base capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a free base capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a malate salt capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a malate salt capsule
Study: NCT02777450

Intervention type: PROCEDURE
Intervention: lumbar facet block
Description: injection of Levobupivacaine 0,25% and corticosteroids
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
Study: NCT00418600

Intervention type: DRUG
Group type: OTHER
Intervention: Hectorol® (doxercalciferol capsules)
Description: Hectorol capsules at 1.0 times current injection dose

Intervention type: DRUG
Group type: OTHER
Intervention: doxercalciferol capsules, Hectorol®
Description: Hectorol capsules at 1.5 times current injection dose

Intervention type: DRUG
Group type: OTHER
Intervention: doxercalciferol capsules, Hectorol® capsules
Description: Hectorol capsules at 2.0 times current injection dose
Study: NCT01435473

Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Study: NCT02552173

Intervention type: RADIATION
Intervention: The Relationship Between Operative and Radiologic Stem Version
Description: intraopertive surgeon's estimation and postoperative CT scan
Study: NCT00626782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin (MMC)
Description: Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
Study: NCT02010775

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
Study: NCT04234178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: 2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal+Epidural
Description: 10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
Study: NCT00592943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: tablet, taken by mouth, once each study day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: tablet, taken by mouth, once each study day
Study: NCT01500694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine HCl (Intuniv, SPD503)
Description: Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
Study: NCT03980002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR and Ibrutinib
Description: Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d
Study: NCT03363568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Inhibitory Control Training
Description: Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adaptive Inhibitory Control Training
Description: Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
Study: NCT04237610

Intervention type: BEHAVIORAL
Intervention: behavioral assessment
Description: Probabilistic learning task

Intervention type: BEHAVIORAL
Intervention: behavioral assessment
Description: Probabilistic learning task

Intervention type: BEHAVIORAL
Intervention: behavioral assessment
Description: Probabilistic learning task
Study: NCT01567475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and rituximab
Description: One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
Study: NCT05179538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cued picture-naming therapy
Description: The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
Study: NCT02418663

Intervention type: DRUG
Group type: OTHER
Intervention: Fluid challenge (250 ml Lactated Ringer's solution)
Description: When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above
Study: NCT04032249

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
Study: NCT04447950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type 2/posterior Quadratus Lumborum block
Description: Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block with Saline
Description: Injection of saline into posterior boundary of Quadratus Lumborum muscle.
Study: NCT03980002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR and Ibrutinib
Description: Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and Thalidomide
Description: Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy.
Study: NCT03935204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,270μg/1.0ml
Description: HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
Study: NCT02893943

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02040506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGN523
Description: Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
Study: NCT04066595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
Study: NCT02906358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based pain self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based pain self-management
Study: NCT02202070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Study: NCT01363024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFGR1877S
Description: Intravenous escalating dose
Study: NCT03323047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Dexamethasone
Description: Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose Dexamethasone
Description: Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral placebo 1 hr pre-operatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Dexamethasone
Description: Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
Study: NCT03958253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolbox for Lung Cancer Screening
Description: -Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~* Patient education materials~* Primary care practice educational materials~* Pack-years/eligibility calculator~* Local referral process guide~* Smoking cessation materials and support~* Shared decision-making guide~* LDCT best practice guidelines
Study: NCT00577395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet once a month for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: tablet, 150 mg once a month for 12 months
Study: NCT04232280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT01327508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIGEN SURESHOT Distal Targeting Instrumentation.
Description: image-guided localization system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free-hand technique
Description: Free-hand technique utilizes x-rays to find screw holes.
Study: NCT01344304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant / Fosaprepitant
Description: Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1
Study: NCT02237001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-based meniscal repair
Description: Suture-based meniscal repair
Study: NCT00416494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg intravenously over 30-90 minutes on day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg intravenously over 30-90 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 intravenously over 2 hours on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 intravenously over 2 hours on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
Study: NCT03567967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and vegetable voucher
Description: Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable voucher
Description: Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
Study: NCT01887730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand washing with soap and water
Description: Can infections be prevented by hand washing with soap and water

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand cleaning with alcohol-containing hand rub
Description: Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01746355

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
Study: NCT01297608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caoted suppository
Description: coated suppository with active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: coated suppository
Description: coated suppository with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coated suppository
Description: coated suppository with placebo
Study: NCT01091714

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
Study: NCT03272386

Intervention type: OTHER
Intervention: Observational study
Description: Completing a questionnaire
Study: NCT06431672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interpersonal group psychotherapy
Description: Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.